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by Elsevier B.V. This is an open accesAbstract Background and objectives: Although the BCG vaccine is usually a safe vaccine, a
number of complications can occur, such as adverse local reactions, regional lymphadenitis,
osteomyelitis and disseminated infection in immunocompromised children, with lymphadenitis
being the most common complication. Our objective to describe the associated clinical char-
acteristics and outcomes.
Materials and methods: This was a prospective observational study conducted over two year’s
period.
Results: 100 patients were enrolled with (62%) males and (38%) females. 93 cases (93%) have
nodes involvement with a total of 103 nodes was reported as follow: Axillary, supraclavicle,
cervical with number of 75(72.8%), 23(22.3%), 5(4.9%) respectively. (55.3%) resulted in suppu-
ration, and (44.7%) with non-suppuration. Only 3 cases (3%) had severe disease with dissemi-
nation, (88.3%) had small size nodes (< 3 cm), and (11.7%) with large size nodes (>3 cm).
(88%) had self-limited disease, and node disappears between (8e168 weeks).
Conclusion: In the Majority of BCG related lymphadenitis is a benign condition with sponta-
neous healing. Also there is Increase incidence of association between BCG vaccine and serious
disseminated infections in immunodeficiency cases.
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Bacillius CalmetteeGuerin (BCG) is a live attenuated vac-
cine derived from a strain of Mycobacterium bovis with a
characteristics residual virulence, has been used to prevent
tuberculosis since 1921 [1].
The World Health Organization (WHO) has recommended
BCG vaccination as part of the global Expanded Program forentre (General Organization), Saudi Arabia. Production and hosting
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tuberculosis (TB) incidence rate of 15 cases/100,000 peo-
ple, the national immunization Program still includes
neonatal BCG vaccination [2]. As of to date the BCG vaccine
strain which is use to vaccinate babies in Saudi Arabia is
Dannish Strain. Although the BCG vaccine is usually a safe
vaccine, a number of complications can occur, such as
adverse local reactions, regional lymphadenitis, osteomy-
litis and disseminated infection in immunocompromised
children, with lymphadenitis being the most common
complications [3].
We conducted this study to describe children with BCG
vaccine related complications and highlight their presen-
tation, course and treatment options.
2. Materials and methods
This study was conducted at King Fahad Medical City
eChildren’s Specialized Hospital, Riyadh. The hospital
provides all levels of care for Riyadh City region as well as a
referral center from all over the Kingdom of Saudi Arabia.
All children who were referred to pediatric infectious dis-
ease clinics with any BCG vaccine complications were
enrolled, date included between June 2011 and June 2013.
All children had received the same type of vaccine (Danish
strain) at birth administered intradermally at the govern-
mental Centers. We used a standardized case report form
with different variables. And all patients were followed
prospectively till one year from their initial presentation
with documented progress.
Data were presented as numbers (percentages), and
median [minimum e maximum].
3. Results
A total of 100 children referred to infectious diseases
Clinics as case of BCG vaccine related complications. Of
whom 62 children (62%) were males and 38 (38%) were fe-
males (Table 1). (92%) were immunocompetent while only
8% were immunocompromised: 4 (4%) IL12 deficiency, 2 (2%)
CGD, 1 (1%) SCID, 1 (1%) HIV, respectively.Table 1 Children characteristics (No: 100 children).
Gender: number (%)
Male 62 (62)
Female 38 (38)
Median age at starting symptoms (weeks) 8 [3e46]
Median age at presentation (weeks) 16 [6e48]
Type of complication: number (%)
Regional lymphadenitis 90 (90)
Disseminated (BCG iosis) 3 (3)
Local reaction (ulcer, discharge, abscess) 7 (7)
Immune status: number (%)
Immunocompetent 92 (92)
Immunocompromised 8 (8)
Data are presented as number (%) and median
[minimumemaximum].Age at observed symptoms ranged between 3 and 46
weeks with a median of 8 weeks. While the time of initial
presentation to the hospital was (6e48) weeks with a me-
dian of 16 weeks. 93 children (93%) have nodes involvement
with a total of 103 nodes was reported as follow: Axillary,
supraclavicle, cervical with number of 75 (72.8%), 23
(22.3%), 5 (4.9%) respectively. 91 (88.3%) of the nodes had
small size (< 3 cm) while 12 nodes (11.8%) with large size
(>3 cm).
57 cases (55.3%) resulted in suppuration, of which 50
cases (87.7%) the abscess ruptured, of which 2 (4%)
complicated by superimposed bacterial infection. 46 cases
(44.7%) were non suppurative lymphadenitis (Table 2).
Node disappears between (8e168 weeks) with a median of
32 weeks. Delayed nodes healing was mostly observed in
immuncompromised children.
Out of the 100 children; 16 (16%) have local reaction at
BCG site in form of discharge scars or subcutaneous abscess
or ulceration, Nine of them with associated lymph node and
seven with only local complications. and 3 (3%) had severe
disease with dissemination (BCGiosis) (Table 1), and all
were immunocompromised with Interleukin-12 (IL 12)
deficiency disease.
The treatment given for these children was assisted as
follow: 84 children (84%) had no treatment due to self-
limited disease, while 16 (16%) end with treatment as
follow: 11 (9%) with antituberculus treatment, 2 (2%) with
surgical intervention, and 3 (3%) with both medical and
surgical intervention.
4. Discussion
In this study, we explored a common but relatively under
recognized problem of post BCG lymphadenopathy.
Post BCG vaccination complications are well
recognized [4]. Mild adverse reactions are considered as
part of the normal reaction [4]. The reported incidence
of these events worldwide is 0.1e17% [5].
The explanation is not fully clear for the noted increase
in BCG related complications [6,7]. The frequency of the
lymphadenitis after vaccination correlates with the type of
vaccine used. Teo et al [8] had demonstrated an increase
in the incidence of lymphadenitis after the introduction of
Danish strain (SSI) type in the United Kingdom. Using thisTable 2 Node characteristics (No: 103 nodes).
Node involved: number (%)
Axillary 75 (72.8)
Supraclavicle 23 (22.3)
Cervicle 5 (4.9)
Type of the node complication: number (%)
Suppurative 57 (55.3)
Ruptured 50 (87.7)
Non ruptured 7 (12.3)
Non suppurative 46 (44.7)
Disseminated (BCG iosis) 3 (3)
Local reaction (ulcer, discharge, abscess) 16 (16)
Size of the node: number (%)
<3 cm 91 (88.3)
>3 cm 12 (11.7)
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less than 1 year should receive a 0.05 ml in contrast to
0.1 ml dose in using the older types [7,8]. The use of a
more reactogenic strain of this vaccine may also explain
such complications. Characteristics of the recipient pop-
ulation may also be a determinant factor in the risk for
complications [7,8]. This may account for the difference in
incidence of complications in different countries. Mori
et al [5] confirmed the age related reported complications;
highest risk of lymphadenopathy is reported in newborn
period [7e9].
Unilateral axillary lymph node enlargement was seen in
75 infants (75%), this is consistent with what is most
commonly seen in a previous study [9,10].
The majority of BCG lymphadenitis develops around 8
weeks after BCG vaccination. The time of node swelling
correlates with the peak of local cutaneous reaction to the
vaccine [5e9].
In our study, suppurative lymphadenitis was seen in 57
nodes (55.3%) which is consistent with what have been
found in other study (30e80%) [11].
Disseminated BCG infection is rare complication with
estimated incidence of 0.1e4.3 per one million vaccinated
children but is lethal in 50e71% of the cases [12,13]. The
death rate is especially higher in cases of immunode-
pression (83%) and it is important to note that a temporary
or permanent immune deficiency is observed in 86% of the
cases [6e12]. However, in some area, the rate of Dissemi-
nated BCG infection even higher which is reaching 22.9%
and the mortality rate is 72.8% [14]. One of the major im-
munodeficiency diseases leading to dissemination of BCG is
defect of 1Le12/INF e gamma axis and can often be lethal
[15]. In our study dissemination disease (BCGiosis) rate was
3% and all cases with 1L-12/INF e gamma axis defect as a
cause of immunodeficiency.
Otherwise, BCG regional lymphadenitis is a self-limiting
complication with no need for either medical or surgical
intervention. Is in contrast to the previous practice in the
Kingdom where antituberculus medications where used
commonly [15]. Nevertheless, we noticed occasionally that
we could avoid node excision in case of large node size by
using isoniazid with or without Rifampin for a period.
However, this may relate to the susceptibility of our cur-
rent strain (Dannish), in difference to which other studies
reported that introduction of antituberculus medications
did not show change in outcome of the large size node
(>3 cm) [16].
Our findings are not in accordance with a previous
Saudi study [15] which was showed that medical treat-
ment in addition to needle aspiration were the most
effective treatment for enlarged lymph nodes. Abdullah
et al [17] reported five cases among eight patients with
iatrogenic sinus formation following needle aspiration. In
contrast to, Paul Hengster et al [18] who proved the
success of surgical excision for the lymph node when it is
exceeding 1.5 cm especially in reducing the healing time.
Also in contrast to other studies [19,20] that demon-
strated a sinus formation following the self-rupture as a
burden we rarely referred a patient for surgical treat-
ments (Needle aspiration/Excision) even with large size
suppurative node that got healed with no complications
following puncture.5. Conclusion
Majority of BCG related lymphadenitis is a benign condi-
tion, and have spontaneous healing. Occasionally, with
large size node, introducing of an antituberculus medica-
tions and/or surgical intervention will be as useful. This
prospective study also shed light on a high rate of associ-
ation between BCG vaccine and serious disseminated in-
fections especially in immunodeficiency cases. Thus, it
would be advisable to administer BCG vaccine at a time
later than at birth.Conflict of interest
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